Tumor‐Specific Multipath Nucleic Acid Damages Strategy by Symbiosed Nanozyme@Enzyme with Synergistic Self‐Cyclic Catalysis
Source abstract
Abstract
Abstract The high proliferation efficiency, redox imbalance, and elevated nucleic acid repair capabilities of tumor cells severely restrict the theranostic efficacy. Selectively interference chaotic tumors with devastating nucleic acid damages (NUDs) properties are expected to overcome theranostic barriers. Here, an exquisite catalytic‐based strategy with comprehensive NUDs mechanisms is demonstrated. In this regard, enzyme (glucose oxidase, GOD) symbioses nanozyme Cu3+x(PO4)2 through biomineralization (abbreviated as Cu@GOD), GOD can disorder the metabolism by consuming glucose, thereby inhibiting the nutrition supply for nucleic acid repair. GOD‐catalyzed H2O2 guarantees the self‐cyclic glutathione depletion and reactive oxygen species generation caused by Cu3+x(PO4)2, resulted the reduced antioxidation defense and enhanced oxidation assault, ensures an indiscriminate NUDs ability. Moreover, the high photothermal effect of Cu3+x(PO4)2 induces effective tumor inhibition. Consequently, this substantial multipath NUDs strategy, with potentials of suppressing the cytoprotective mechanisms, amplifying the cellular oxidative stress, and disrupting the redox balance to ensure substantial irreversible NUDs, completely breaks the obstacle of chaotic tumors, providing new conceptual thinking for tumor proliferation inhibition.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Advanced Nanomaterials in Catalysis · Nanoplatforms for cancer theranostics · Advanced biosensing and bioanalysis techniques
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
State Key Laboratory for Chemo/Biosensing and Chemometrics College of Chemistry and Chemical Engineering Hunan University Changsha Hunan 410082 China
Key Laboratory of Optic‐electric Sensing and Analytical Chemistry for Life Science MOE Shandong Key Laboratory of Biochemical Analysis College of Chemistry and Molecular Engineering Qingdao University of Science and Technology Qingdao 266042 China
Department of Radiology The Third Xiangya Hospital of Central South University Changsha Hunan 410013 China
References (53)
Show source-provided references
1. 10.1146/annurev-biochem-011520-10472210.1146/annurev-biochem-011520-104722 ↗
2. 10.1016/j.molcel.2016.08.00410.1016/j.molcel.2016.08.004 ↗
3. Crunkhorn S. · Nat. Rev. Drug Discovery · 2018 · 17 · 18
4. 10.1016/j.tibs.2018.02.01010.1016/j.tibs.2018.02.010 ↗
5. 10.1016/j.tcb.2019.11.00310.1016/j.tcb.2019.11.003 ↗
6. 10.1038/s41577-019-0135-610.1038/s41577-019-0135-6 ↗
7. 10.1158/1078-0432.CCR-18-252310.1158/1078-0432.CCR-18-2523 ↗
8. 10.1038/s41467-018-03903-810.1038/s41467-018-03903-8 ↗
9. 10.1002/adma.20200224610.1002/adma.202002246 ↗
10. 10.1002/adma.20200356310.1002/adma.202003563 ↗
11. 10.1002/adfm.20170508610.1002/adfm.201705086 ↗
12. 10.1016/j.addr.2017.10.00410.1016/j.addr.2017.10.004 ↗
13. 10.1016/j.pharmthera.2020.10762710.1016/j.pharmthera.2020.107627 ↗
14. 10.1002/smll.20190212310.1002/smll.201902123 ↗
15. 10.1126/sciadv.abb269510.1126/sciadv.abb2695 ↗
16. 10.1083/jcb.20170102610.1083/jcb.201701026 ↗
17. Zhao H. · Oncol. Lett. · 2019 · 17 · 42
18. 10.1016/j.toxlet.2020.06.01910.1016/j.toxlet.2020.06.019 ↗
19. 10.1002/em.2220910.1002/em.22209 ↗
20. 10.1016/j.biotechadv.2020.10758410.1016/j.biotechadv.2020.107584 ↗
21. 10.1002/tcr.20160000710.1002/tcr.201600007 ↗
22. 10.1002/adma.20180536810.1002/adma.201805368 ↗
23. 10.1039/C7CS00891K10.1039/C7CS00891K ↗
24. 10.1002/adfm.20191008510.1002/adfm.201910085 ↗
25. 10.1021/acs.nanolett.9b0093410.1021/acs.nanolett.9b00934 ↗
26. 10.1002/anie.20191614210.1002/anie.201916142 ↗
27. 10.1021/jacs.9b0658910.1021/jacs.9b06589 ↗
28. 10.1021/jacs.0c0028510.1021/jacs.0c00285 ↗
29. 10.1016/j.solener.2017.11.00510.1016/j.solener.2017.11.005 ↗
30. 10.1039/C9TB02294E10.1039/C9TB02294E ↗
31. 10.1039/B811842F10.1039/B811842F ↗
32. 10.1039/C2CS35347D10.1039/C2CS35347D ↗
33. 10.1002/anie.20190972910.1002/anie.201909729 ↗
34. 10.1002/adfm.20190795410.1002/adfm.201907954 ↗
35. 10.1093/nar/gkn99310.1093/nar/gkn993 ↗
36. 10.1016/j.redox.2018.10108410.1016/j.redox.2018.101084 ↗
37. 10.1016/j.celrep.2020.02.11410.1016/j.celrep.2020.02.114 ↗
38. 10.1146/annurev-pathol-012615-04444610.1146/annurev-pathol-012615-044446 ↗
39. 10.1021/acsami.9b1693410.1021/acsami.9b16934 ↗
40. 10.1021/acs.nanolett.9b0355610.1021/acs.nanolett.9b03556 ↗
41. 10.1002/anie.20190675810.1002/anie.201906758 ↗
42. 10.1002/adfm.20190141710.1002/adfm.201901417 ↗
43. 10.1039/C6CS00592F10.1039/C6CS00592F ↗
44. 10.1039/c3cs60048c10.1039/c3cs60048c ↗
45. 10.1126/science.aaf440510.1126/science.aaf4405 ↗
46. 10.1515/revneuro-2017-007510.1515/revneuro-2017-0075 ↗
47. 10.1039/C9BM01354G10.1039/C9BM01354G ↗
48. 10.1016/j.jconrel.2018.01.03410.1016/j.jconrel.2018.01.034 ↗
49. 10.1016/j.redox.2016.02.00210.1016/j.redox.2016.02.002 ↗
50. 10.1016/j.ccell.2017.11.01510.1016/j.ccell.2017.11.015 ↗
51. Price M. N. · mSystems · 2019 · 4 · 00297
52. 10.1016/j.redox.2017.05.01110.1016/j.redox.2017.05.011 ↗
53. 10.1016/S0891-5849(00)00480-910.1016/S0891-5849(00)00480-9 ↗